英语母语专家为您的论文保驾护航

Kim Rice



  • Kim Rice
    更多

    2004 - PhD Molecular Biology, Murdoch University

    1998 - BSc, Murdoch University


    Dr Rice曾在纽约西奈山医学院血液/肿瘤科以及西北大学Robert H. Lurie 综合性肿瘤中心工作。博士后期间主要研究转路抑制机制,致力于t(11;17) APL中发现的PLZF和PLZF-RARa是如何通过此机制对融合癌蛋白基因表达进行调控,且在其失调后如何最终导致白血病的形成。Dr Rice曾进行过全基因筛选和相关通路及候选染色体的判定,以便针对有选择性的治疗靶向做出可检验的假设。此外,还曾与Dana-Farber癌症研究所(波士顿)和麦吉尔大学(蒙特利尔)的独立研究人员多次进行项目合作,试验癌蛋白转化细胞对特定药物配方的敏感度。曾在Blood、Genes and Development以及Blood Cancer Journal等多家国际知名期刊上发表文章,并为PNAS、Blood、Oncogene和Leukemia担任审稿人。与他人合作撰写了两篇专书论文,并在美国血液病学会的多个会议场合发表。自2011年起开始为理文编辑工作。

    Dr Rice worked within the Division of Hematology/Oncology at the Mount Sinai School of Medicine in New York and at the Robert H. Lurie Comprehensive Cancer Centre of Northwestern University. Dr Rice’s Post-Doctoral studies focused on transcriptional mechanisms by which PLZF and the PLZF-RARa fusion oncoprotein found in t(11;17) APL regulate gene expression, and ultimately how their dysregulation contributes to leukemogenesis. Dr Rice has experience in performing whole genome screens and identifying relevant pathways and candidate genes to formulate testable hypothesis with the aim of selective, therapeutic targeting. She was also involved in several collaborative projects with independent researchers at the Dana-Farber Cancer Institute (Boston) and McGill University (Montreal) testing the sensitivity of oncoprotein-transformed cells to specific drug compounds. Dr Rice has published in internationally recognized journals including Blood, Genes and Development and Blood Cancer Journal and has reviewed for PNAS, Blood, Oncogene and Leukemia. She has also written two book chapters and presented her work on several occasions at American Society of Hematology meetings. Dr Rice began editing for the Edanz Group in 2011.